Literature DB >> 18070284

Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma.

F Farinati1, R Cardin, M Bortolami, P Burra, F P Russo, M Rugge, M Guido, A Sergio, R Naccarato.   

Abstract

Epidemiological evidence clearly identifies chronic infection with hepatitis C virus (HCV) as a major risk factor for the development of hepatocellular carcinoma (HCC). Among the mechanisms that have been implicated in the pro-carcinogenic effect of HCV infection, an increased production of reactive oxygen species in the liver seems to have a major pathogenetic role in leading from chronic inflammation to cancer. Recent data have also demonstrated that HCV is capable of inducing this active production of free radicals per se, not just through inflammation, a feature peculiar to this virus and the specific activity of its core protein. This paper provides an overview of the inter-relationships between HCV, liver damage, free radical production and HCC, describing at least in part the complex network involving DNA oxidative damage, cytokine synthesis, proto-oncogene activation and oestrogen receptor expression, that may all be deeply involved in liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070284     DOI: 10.1111/j.1365-2893.2007.00878.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

1.  Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.

Authors:  Martin R Higgs; Hervé Lerat; Jean-Michel Pawlotsky
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

5.  Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model.

Authors:  Kai-Wen Huang; Hui-Lin Wu; Hsiu-Lin Lin; Po-Chin Liang; Pei-Jer Chen; Shih-Hui Chen; Hsin-I Lee; Pei-Yi Su; Wen-Hsuan Wu; Po-Huang Lee; Lih-Hwa Hwang; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

6.  Association between hepatitis C and hepatocellular carcinoma.

Authors:  Luis Jesuino de Oliveria Andrade; Argemiro D'Oliveira; Rosangela Carvalho Melo; Emmanuel Conrado De Souza; Carolina Alves Costa Silva; Raymundo Paraná
Journal:  J Glob Infect Dis       Date:  2009-01

7.  Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.

Authors:  Andromachi Kotsafti; Fabio Farinati; Romilda Cardin; Patrizia Burra; Marina Bortolami
Journal:  BMC Gastroenterol       Date:  2010-04-01       Impact factor: 3.067

Review 8.  Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment.

Authors:  Giuseppe Castello; Susan Costantini; Stefania Scala
Journal:  J Transl Med       Date:  2010-11-03       Impact factor: 5.531

9.  Role of free radicals in liver diseases.

Authors:  Pablo Muriel
Journal:  Hepatol Int       Date:  2009-11-26       Impact factor: 6.047

Review 10.  Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases.

Authors:  Elizabeth Ma Rabelo-Gonçalves; Bruna M Roesler; José Mr Zeitune
Journal:  World J Hepatol       Date:  2015-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.